

关于汇丰代客境外理财计划-开放式海外基金型产品所投资的汇丰环球股票可持续健康护理基金投资目标变更的通知

注意：本通知包含重要信息，您须仔细阅读全部内容，如有任何疑问，请您及时联系客户经理或拨打我行客户服务热线 95366。

尊敬的客户，

感谢您对汇丰银行（中国）有限公司（“我行”）一直以来的支持。针对您持有的投资于汇丰环球股票可持续健康护理基金的汇丰代客境外理财计划 - 开放式海外基金型产品（产品编码：IPFD2273/IPFD2274/IPFD2275/IPFD2276/IPFD2277/IPFD3273/IPFD3274/IPFD3275/IPFD2276），我行近期获汇丰环球投资管理有限公司（“基金公司”）通知，该海外基金已于2022年1月3日对投资目标进行变更。为此，我行特通知如下：

1. 调整详情

据基金公司的通知，自2022年1月3日起，汇丰环球股票可持续健康护理基金的投资目标将发生变更。该变更并不会影响本基金的核心投资目标和风险状况。本基金依然旨在透过投资可从全球日益受限制的医疗预算中受益的公司股票组合，提供长期资本增值及收益，且基金持有人支付的费用不会发生改变。

变更原因：

变更旨在更详细地阐述投资政策、并提供标的行业分析的更多细节。将至少80%的净资产投资于在任何国家（包括已成熟市场及新兴市场）注册、位于该国、在该国进行商业活动或在该国受规管市场上市的可持续医疗保健公司的股票及等同股票的证券降低为70%，是为了与市场标准相统一，且70%的持仓能够充分反映该基金的投资策略。

具体变更如下：

新的投资目标（改动部分以红色标注）

本基金旨在投资于有望从日益受限的全球医疗保健预算中受益的公司的集中股票组合，提供长线总回报，同时促进欧盟 SFDR 第 8 条界定的 ESG（即环境、社会、治理）特点。

本基金旨在透过投资于当前及 / 或预期收入涉及**创新型**可持续医疗保健的**主题和**产品的公司来实现这一目标。**可持续医疗保健产品有潜力透过提高临床效益（例如提高临床疗效、安全性）及 / 或透过创新节省成本（例如降低治疗成本、降低持续住院成本）来提升医疗保健开支的资金价值。此类公司（「可持续医疗保健公司」）由包括可持续医疗保健评分（「可持续医疗保健评分」）在内的汇丰专有分析流程厘定，**

如下所述。本基金的目标符合联合国可持续发展目标的第三项，即专注于良好健康与福祉的社会目标。

本基金将把至少 80%70%的净资产投资于在任何国家（包括已成熟市场及新兴市场）注册、位于该国、在该国进行商业活动或在该国受规管市场上市的可持续医疗保健公司的股票及等同股票的证券。可持续医疗保健主题和产品可包括但不限于，可帮助减少患者在深切治疗部所花时间的药物，可在早期检测及治疗的诊断测试，疾病预防、操作改进及科技部署。本基金相对集中投资于注册地为美国的公司股票。

对医疗保健行业及子行业进行基本因素分析以识别呈现投资机会的公司。然后，对每家已识别的公司进行专有分析，研究其目前或预计将成为产生最高收入，至少占当前收入净值所产生总价值 10%的产品。该专有分析用于根据有所提高的临床效益和成本节省来确定每种产品的可持续医疗保健评分。每种产品的评分范围由-3 至+3，或采用类似的评分表。此后，每家已识别公司的总体可持续医疗保健评分将计算为产生最高收入的产品可持续医疗保健评分的平均值，按公司当前收入净值所产生的价值加权。可持续医疗保健评分为零或正数的公司被视为可持续医疗保健公司。

在评估相关公司的可持续医疗保健评分和 ESG 特性时，投资顾问可倚赖成熟数据提供商（如适用）及 / 或其专属研究提供的专业知识、研究及数据。

有关汇丰投资管理的负责任投资政策的更多资料刊登于

<https://www.assetmanagement.hsbc.com.hk/en/individual-investor/about-us/responsible-investing/policies>（该网站未经证监会审核）。

本基金可将其最多 20%的净资产透过沪港股票市场交易互联互通机制及 / 或深港股票市场交易互联互通机制投资于中国 A 股，及其最多 20%的净资产投资于中国 A 股连接产品。本基金对中国 A 股（透过沪港股票市场交易互联互通机制、深港股票市场交易互联互通机制或中国 A 股连接产品）及中国 B 股的最大总投资参与为其净资产的 40%。本基金不会将其超过 10%的净资产投资于由中国 A 股连接产品任何单一发行人发行的中国 A 股连接产品。

本基金可将其最多 40%的净资产投资于在深圳证券交易所创业板（「创业板」）及 / 或在上海证券交易所科创板（「科创板」）上市的股票。

以上摘自基金公司的通知，且仅体现了该通知的部分内容，您可以且应当主动参阅基金公司公示的有关本公司的完整通知。

完整通知请参考附录部分(仅包含英文通知)。

2. 若您持有汇丰代客境外理财计划-开放式海外基金型产品-汇丰环球股票可持续健康护理基金

代客境外理财计划下之相关海外基金名称	海外基金 ISIN 代码	参考编号	风险水平	全国银行业理财信息登记系统登记编码#
汇丰环球股票可持续健康护理基金-美元-累计	LU2324357040	IPFD2273/IPFD3273	5（最高风险）	C1050121000022
汇丰环球股票可持续健康护理基金-美元-累计	LU2324357040	IPFD2273/IPFD3273	5（最高风险）	C1050121000022
汇丰环球股票可持续健康护理基金-港元-累计	LU2324359764	IPFD2274/IPFD3274	5（最高风险）	C1050121000023
汇丰环球股票可持续健康护理基金-港元-累计	LU2324359764	IPFD2274/IPFD3274	5（最高风险）	C1050121000023
汇丰环球股票可持续健康护理基金-港元-累计	LU2324358014	IPFD2275/IPFD3275	5（最高风险）	C1050121000024

基金- 欧元对冲 - 累计				
汇丰环球股票可持续健康护理基金- 欧元对冲 - 累计	LU2324358014	IPFD2275/IPFD3275	5 (最高风险)	C1050121000024
汇丰环球股票可持续健康护理基金- 澳元对冲 - 累计	LU2324359848	IPFD2276/IPFD3276	5 (最高风险)	C1050121000025
汇丰环球股票可持续健康护理基金- 澳元对冲 - 累计	LU2324359848	IPFD2276/IPFD3276	5 (最高风险)	C1050121000025
汇丰环球股票可持续健康护理基金- 人民币对冲 - 累计	LU2324359921	IPFD2277	5 (最高风险)	C1050121000026

#可依据该编码在「中国理财网」(www.chinawealth.com.cn)查询该产品信息

针对您持有的对应于该海外基金的理财计划单位，您可根据您的个人情况作出适当投资决定，即继续持有、选择赎回或转换为另一只可转换的基金。

重要提示：

理财非存款、产品有风险、投资须谨慎。我行提供以上信息并非也不应被视为关于投资、持有或赎回任何产品的建议。投资有风险，过往表现不代表也不预示将来表现。您可根据您的个人情况（包括但不限于，您的风险偏好、投资经验、投资目标和财务状况等），考虑和自行决定继续持有、赎回或转出相关代客境外理财产品。您若有任何疑问或者希望了解更详细的信息，您可随时垂询您的客户经理或拨打我行客服热线95366。

谢谢！

HSBC Global Investment Funds
Société d'Investissement à Capital Variable
 16, boulevard d'Avranches
 L-1160 Luxembourg
 Grand-Duchy of Luxembourg
 R.C.S. Luxembourg B 25.087

Dear Shareholder,

We are writing to inform you that the investment objective of HSBC Global Investment Funds – Global Equity Sustainable Healthcare, a sub-fund in which you own shares (the “**Sub-Fund**”), will change on 3 January 2022 to reflect the enhanced investment objective.

The core investment objective and risk weighting of the Sub-Fund is not changing. The continuing aim is to provide long-term total return in a concentrated portfolio of equities of companies that may benefit from increasingly constrained healthcare budgets world-wide, while promoting ESG characteristics within the meaning of Article 8 SFDR. Fees paid by shareholders will not change.

Please take a moment to review the important information given below. If you have any questions, please contact your local agent or HSBC Asset Management office.

You do not need to take any action. However, you do have three options that are explained below.

For and on behalf of the Board of HSBC Global Investment Funds

The Changes

Current Investment Objective	New Investment Objective
<p>The sub-fund aims to provide long term total return by investing in a concentrated portfolio of equities of companies that may benefit from increasingly constrained healthcare budgets world-wide, while promoting ESG characteristics within the meaning of Article 8 of SFDR. The sub-fund aims to do this by investing in companies with revenue exposure to innovative sustainable healthcare themes and products which have the potential to improve value for money of healthcare spending (“Sustainable Healthcare Themes and Products”). The sub-fund’s aims are aligned with goal three of the UN Sustainable Development Goals, which is a social goal focused on good health and well-being.</p>	<p>The sub-fund aims to provide long term total return by investing in a concentrated portfolio of equities of companies that may benefit from increasingly constrained healthcare budgets world-wide, while promoting ESG characteristics within the meaning of Article 8 of the European Union’s SFDR.</p> <p>The sub-fund aims to do this by investing in companies with current and/or expected revenue exposure to innovative sustainable healthcare themes and products which (“Sustainable Healthcare Products”). Sustainable Healthcare Products have the potential to improve value for money of healthcare spending (“Sustainable Healthcare Themes and Products”) through improved clinical benefits (e.g. improved clinical efficacy, safety) and/or cost savings through innovation (e.g. a reduction in treatment costs, reduction in ongoing hospitalisation costs). Such companies (“Sustainable Healthcare Companies”)</p>

The sub-fund will invest a minimum of 80% of its net assets in equities and equity equivalent securities of companies with at least two thirds of their revenues derived from Sustainable Healthcare Themes and Products, which are domiciled in, based in, carry out business activities in, or are listed on a Regulated Market in, any country including both developed and Emerging Markets. Sustainable Healthcare Themes and Products may include, but are not limited to, drugs which help reduce the days a patient spends in an intensive care unit, diagnostic tests which enable early detection and treatment, disease prevention, operational improvements and deployment of technology.

Fundamental analysis of the healthcare sector and sub-sectors is undertaken to identify companies that present an investment opportunity. Following this, proprietary analysis of each identified company is undertaken to assess exposure to Sustainable Healthcare Themes and Products. This generates a sustainable healthcare score based on a combination of clinical benefits and cost savings. These scores are used, together with consideration of ESG characteristics, to define the sub-fund's eligible investment universe.

are determined based on a HSBC proprietary analysis process including sustainable healthcare scores ("Sustainable Healthcare Scores"), as described below. The sub-fund's aims are aligned with goal three of the UN Sustainable Development Goals, which is a social goal focused on good health and well-being.

The sub-fund will invest a minimum of ~~80~~70% of its net assets in equities and equity equivalent securities of ~~companies with at least two thirds of their revenues derived from~~ Sustainable Healthcare Themes and Products Companies, which are domiciled in, based in, carry out business activities in, or are listed on a Regulated Market in, any country including both developed and Emerging Markets. Sustainable Healthcare Themes and Products may include, but are not limited to, drugs which help reduce the days a patient spends in an intensive care unit, diagnostic tests which enable early detection and treatment, disease prevention, operational improvements and deployment of technology. The sub-fund may be relatively concentrated in equities of companies domiciled in the USA.

Fundamental analysis of the healthcare sector and sub-sectors is undertaken to identify companies that present an investment opportunity. ~~Following this~~For each identified company, proprietary analysis ~~of each identified company~~ is then undertaken on their products that are currently, or expected to become, their top revenue generating products, representing at least 10% of their net present revenue generating value in aggregate ~~to assess exposure to Sustainable Healthcare Themes and Products. This generates a sustainable healthcare score based on a combination of clinical benefits and cost savings. These scores are used, together with consideration of ESG characteristics, to define the sub-fund's eligible investment universe.~~ This proprietary analysis is used to determine Sustainable Healthcare Scores for each product according to both improved clinical benefits and cost savings. Scores can range from -3 to +3 or a similar scoring scale for each product. Following this, the overall Sustainable Healthcare Scores for each identified company will be calculated as the average of their top revenue generating products' Sustainable Healthcare Scores, weighted by their net present revenue generating values. Companies with zero to

<p>When assessing companies' sustainable healthcare score and ESG characteristics, the Investment Adviser may rely on expertise, research and information provided by well-established financial data providers (when available) and/or its own proprietary research.</p> <p>More information on HSBC Global Asset Management's responsible investing policies is available at www.assetmanagement.hsbc.co.uk/en/intermediary/about-us/responsible-investing/policies.</p> <p style="text-align: center;">~~~</p> <p>The sub-fund may invest up to 20% of its net assets in China A-shares through the Shanghai-Hong Kong Stock Connect and/or the Shenzhen-Hong Kong Stock Connect and up to 20% of its net assets in CAAPs. The sub-fund's maximum exposure to China A-shares (through the Shanghai-Hong Kong Stock Connect, the Shenzhen-Hong Kong Stock Connect or CAAP) and China B-shares is 40% of its net assets. The sub-fund will not invest more than 10% of its net assets in CAAPs issued by any single issuer of CAAPs.</p>	<p>positive Sustainable Healthcare Scores are considered Sustainable Healthcare Companies.</p> <p>When assessing companies' sustainable healthcare score and ESG characteristics Sustainable Healthcare Scores, the Investment Adviser may rely on expertise, research and information provided by well-established financial data providers (when available) and/or its own proprietary research.</p> <p>More information on HSBC Asset Management's responsible investing policies is available at www.assetmanagement.hsbc.com/about-us/responsible-investing/policies.</p> <p style="text-align: center;">~~~</p> <p>The sub-fund may invest up to 20% of its net assets in China A-shares through the Shanghai-Hong Kong Stock Connect and/or the Shenzhen-Hong Kong Stock Connect and up to 20% of its net assets in CAAPs. The sub-fund's maximum aggregate exposure to China A-shares (through the Shanghai-Hong Kong Stock Connect, the Shenzhen-Hong Kong Stock Connect or CAAP) and China B-shares is 40% of its net assets. The sub-fund will not invest more than 10% of its net assets in CAAPs issued by any single issuer of CAAPs.</p> <p>The sub-fund may invest up to 40% of its net asset value in stocks listed on the ChiNext Board of the Shenzhen Stock Exchange (the "ChiNext board") and/or the Science and Technology Innovation Board of the Shanghai Stock Exchange (the "STAR Board").</p>
---	---

Reason for the Investment Objective change

The above changes are a clarification of the investment policy of the Sub-Fund and provides more detail on the underlying sector analysis undertaken. Reducing the minimum 80% of the Sub-Fund invested in the defined universe of instruments brings it into line with market standards. Exposure of 70% adequately reflects the underlying investment strategy.

Your Options

- 1. Take no action.** Your investment will remain as it is today.
- 2. Convert your investment to another HSBC Global Investment Funds sub-fund.** If you wish to ensure the conversion is completed before the changes become effective, instructions must be received before the implementation date as given in the right-hand column. Please ensure you read the Key Investor Information Document of the sub-fund you are considering.
- 3. Redeem your investment.** If you wish to ensure your redemption is completed before the changes become effective, instructions must be received before the implementation date as given in the right-hand column.

Options 2. and 3. may have tax consequences. You may want to review these options with your tax adviser and your financial adviser.

Regardless of which option you choose, you will not be charged any conversion or redemption fees by HSBC. Please note that some distributors, paying agents, correspondent banks or intermediaries might charge switching and/or transaction fees or expenses at their own discretion.

Terms not defined in this letter will have the same meaning as those defined in the current prospectus of HSBC Global Investment Funds.

The Board accepts responsibility for the accuracy of the information contained in this letter as at the date of the mailing.

CHANGE IMPLEMENTATION DATE:
3 January 2022

THE SUB-FUND: HSBC Global Investment Funds – Global Equity Sustainable Healthcare

THE FUND

HSBC Global Investment Funds

Registered Office 16 boulevard d'Avranches, L-1160 Luxembourg, grand duchy of Luxembourg

Registration Number B 25 087

Management Company HSBC Investment Funds (Luxembourg) S.A.